New 2025 Data Sheds Light on 340B Activity in Georgia
Pioneer Institute has released updated #340B state fact sheets for 2025
The Pioneer Institute has released updated 340B State Fact Sheets for 2025, offering a detailed look into how the 340B Drug Pricing Program is operating in each state—including Georgia. The findings raise key questions about equity, oversight, and impact on low-income communities.
In Georgia:
- 30% of the state’s 340B contract pharmacies are located outside of Georgia, including some as far away as Hawaii.
- 43% of contract pharmacies intended to serve low-income Georgians are actually located in affluent neighborhoods.
- Some hospitals, such as Northside Hospital and AU Medical Center, operate dozens of contract pharmacies—many out of state—while others serve patients effectively with far fewer.
- PBM-owned and chain pharmacies dominate the list of top 340B contract pharmacies in Georgia.
- Despite these concerns, Georgia 340B hospitals reported above-average charity care: 4.92% of operating expenses compared to the national average of 2.15%.
The data also explores:
- Which hospitals have the most (and most out-of-state) contract pharmacies
- How charity care levels vary between insured and uninsured patients
- The correlation between hospital wealth and charitable contributions
➡️ View Georgia’s full 2025 fact sheet and explore national comparisons: https://pioneerinstitute.org/340babuse/340b-state-fact-sheets
As policymakers continue to examine the effectiveness and transparency of the 340B program, this report highlights the importance of tracking how resources intended for underserved populations are actually being deployed.
Georgia Life Sciences is proud to be featured in the latest issue of Inside Medicine Magazine – Atlanta, highlighting the continued growth and impact of Georgia’s life sciences ecosystem.This inaugural issue represents something truly special. Atlanta’s healthcare and life sciences community is driven by innovation, collaboration, and outstanding leadership—and we’re honored to be part of this exciting launch. We’re proud to help showcase the people and organizations advancing healthcare across our region and beyond. Read our feature here: https://hubs.la/Q04876WJ0
B y Trevor Williams , March 24, 2026 | Global Atlanta More than 60 Belgian firms have found a home in Georgia, but nothing on this scale has yet been seen in the state. The amalgam of Belgian investment, carried out over a half-century, translates to about 5,000 current jobs. Gwinnett offered $174 million in incentives to win the project, including property tax abatements, fee waivers and utility improvements, according to Rowen. UCB is set to bring in artificial intelligence, advanced robotics and automation at the site. Biologics are therapies made from living organisms, promising cutting-edge research and manufacturing. Maria Thacker Goethe , president and CEO of Georgia Life Sciences , said the move gives state leaders even more impetus to work collaboratively to build Georgia’s talent pipeline “across every stage — from high school exposure and technical credentials to community college, university, and incumbent-worker upskilling.” “UCB’s decision underscores the strength of Georgia’s talent base, manufacturing capacity, and collaborative business climate, and it reflects the kind of long-term investment that helps build a more resilient U.S. biomanufacturing footprint,” Ms. Goethe told Global Atlanta in an email. Nine of the 16 FDA approvals for UCB drugs and therapies have come within the last three years, showing its prioritization of the U.S. market, where headcount has grown 73 percent since 2017 to 2,000 people. UCB’s products treat severe neurological and immunological conditions like epilepsy, lupus, Parkinson’s disease, rheumatoid arthritis and many more. Read the full article here: UCB Sticks With Georgia, Placing $2 Billion Bet on State’s Life Sciences Ecosystem - Global Atlanta
Georgia Life Sciences leads effort to establish bipartisan caucus focused on advancing the state’s growing life sciences economy
